新基发行创近三年新高 ETF等被动基金占比近六成 新基金发行迎来小高峰。公募排排网数据显示，今年以来全市场共计发行公募基金1378只，这一数字远 超去年全年的1143只，创下近3年的新高，同时也终止了基金发行连续3年下滑的颓势。新基平均认购天 数为16.31天，与去年22.63的平均认购天数相比，募集周期明显大幅缩短，进一步验证了基金发行市场 的回暖。基金发行浪潮中，指数化投资的崛起格外引人注目。在今年发行的1378只新基中，指数型基金 的数量达到813只，占到总量的59%，直观地展现出指数化投资在市场中的热度与重要性。此外，"日光 基"再现，年内已有7只主动权益基金一日售罄并启动比例配售。（智通财经） 国内部分品牌金饰价格三连跌 记者查询到，国内部分品牌金饰价格从14日开始已实现三连跌，其中，老庙黄金足金饰品今日报价1289 元/克，较13日下跌36元/克；老凤祥足金饰品今日报价1293元/克，较13日下跌32元/克。周大福今日报 价1305元/克，较14日高点下跌28元，周生生足金饰品今日报价1305元/克，较14日高点下跌23元/克。 (中新经纬) 易方达基金提示QDII溢价风险 易方达基金公告表示，旗 ...

格隆汇11月17日｜据21财经，近日，默沙东与Cidara Therapeutics共同宣布，双方已签署最终协议，根 据该协议，默沙东将以约92亿美元的总额收购Cidara。这一消息发布后，位于圣地亚哥的生物技术公司 Cidara的股价应声飙升超105%，创下2017年以来的最高水平。而这笔交易的核心筹码是Cidara的核心候 选药物CD388，这是一种基于创新Drug-Fc Conjugate（DFC）技术平台的长效抗病毒药物，用于流感预 防。根据公开信息，在传统流感疫苗平均预防效力仅为40%左右的背景下，CD388在2b期临床试验中最 高剂量展现出76%的预防效力，且单次用药可提供长达4～5个月的保护。"若CD388成功获批上市，其 展现出的76%预防效力远高于传统疫苗，有望打开百亿美元级市场。结合默沙东成熟的商业化网络与全 球渠道，协同效应下净现值（NPV）或远超收购成本。默沙东近年持续加码传染病领域布局（如新冠药 物Lagevrio、HPV疫苗Gardasil等），此次收购其希望通过引入Cidara的专有Cloudbreak平台技术，进一 步强化在'免疫激活型抗感染药物'领域的管线厚度，为中长期增长储 ...

根据公开信息，在传统流感疫苗平均预防效力仅为40%左右的背景下，CD388在2b期临床试 验中最高剂量展现出76%的预防效力，且单次用药可提供长达4～5个月的保护。 "若CD388成功获批上市，其展现出的76%预防效力远高于传统疫苗，有望打开百亿美元级市 场。结合默沙东成熟的商业化网络与全球渠道，协同效应下净现值（NPV）或远超收购成 本。默沙东近年持续加码传染病领域布局（如新冠药物Lagevrio、HPV疫苗Gardasil等），此 次收购其希望通过引入Cidara的专有Cloudbreak平台技术，进一步强化在'免疫激活型抗感染 药物'领域的管线厚度，为中长期增长储备新引擎。"有券商医药行业分析师对21世纪经济报道 记者表示。 在上述分析师看来，从交易时点来看，Cidara正处于核心产品CD388数据验证的关键阶段，3 期ANCHOR研究（高风险人群）结果虽未披露，但预期乐观。此时，默沙东以合理溢价收 购，锁定"潜在First-in-Class"资产，避免了后续研发风险和竞对抬价，符合大型药企"前瞻性 并购+降低不确定性"的常规逻辑。 面对王牌抗癌药Keytruda（帕博利珠单抗）即将面临的专利悬崖危机， ...

Core Insights - Merck (MSD) has acquired Cidara Therapeutics for approximately $9.2 billion, primarily for its innovative flu drug CD388, which has shown a prevention efficacy of up to 76% in Phase 2 clinical trials [1][2][3] - The acquisition is seen as a strategic move to mitigate the impending patent cliff of Merck's leading cancer drug Keytruda, which is expected to lose patent protection by 2028, potentially resulting in a revenue loss of around $18 billion [4][9] - The market reacted positively to the acquisition, with Cidara's stock surging over 105% following the announcement, reflecting strong investor confidence in the potential of CD388 and Merck's long-term value [3][4] Company Strategy - Merck aims to strengthen its pipeline in the infectious disease sector, leveraging Cidara's proprietary Cloudbreak platform technology to enhance its portfolio of immune-activating anti-infection drugs [2][9] - The acquisition price of $221.50 per share indicates Merck's high regard for Cidara's core asset CD388 and its urgent need for new growth drivers amid stagnant performance [2][3] - Merck's recent financial performance shows total revenue of $48.611 billion for the first three quarters, with pharmaceutical revenue at $43.299 billion, highlighting the need for new products to sustain growth [3][4] Market Potential - If CD388 receives regulatory approval, it could tap into a market worth over $10 billion, given its superior efficacy compared to traditional vaccines [2][6] - The global flu vaccine market is projected to grow from $5.8 billion in 2020 to $8.9 billion by 2024, with a compound annual growth rate (CAGR) of 11.2%, indicating a robust demand for flu prevention products [7] - CD388's unique mechanism of action could address significant gaps in the current flu prevention market, particularly for populations that are vaccine-averse or have inadequate responses to vaccines [8][9] Innovation and Future Outlook - The CD388 drug represents a shift from traditional vaccines to innovative preventive therapies, potentially revolutionizing flu prevention and opening avenues for treatments against other viral diseases [9][10] - The FDA has granted CD388 breakthrough therapy designation and fast track status, which could expedite its path to market if Phase 3 trials are successful [6] - The global flu treatment market is expanding steadily, and innovative therapies like CD388 are expected to create high-growth opportunities within this space [10]